🇺🇸 Rheum Palmatum Root in United States
2 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 2
Most-reported reactions
- Condition Aggravated — 1 report (50%)
- Vanishing Bile Duct Syndrome — 1 report (50%)
Other Gastroenterology approved in United States
Frequently asked questions
Is Rheum Palmatum Root approved in United States?
Rheum Palmatum Root does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Rheum Palmatum Root in United States?
CHEN De-chang is the originator. The local marketing authorisation holder may differ — check the official source linked above.